NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
University of Kansas Medical Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Peking University
Peking University
RedHill Biopharma Limited
Shandong Cancer Hospital and Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest